Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Keep An Eye On Ico Therapeutics

(Editor's Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

iCo Therapeutics (ICO.V) (OTCQX:ICOTF) is a small cap Canadian biotechnology company focused on the development of novel therapeutics for the treatment of ophthalmologic and infectious diseases. The company's lead development candidate is iCo-007, a second generation antisense drug for the treatment of diabetic macular edema. The completion of enrollment for the 208 patient iDEAL trial was announced in June 2013, and top-line results are expected in the first quarter of 2014.

Our interest in iCo Therapeutics follows in part from our previous survey, which found a high level of Phase II clinical success associated with locally administered antisense drugs.

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details